Business

INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent

SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company’s proprietary INVOcell device. The new patent extends intellectual property protection on the Company’s INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to si

articleInvo Fertility, Inc.June 25, 20254/company/invo-fertility-inc/news/invo-fertility-receives-notice-allowance-130000580
INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent

About this update from Invo Fertility, Inc.

[{"type":"image","alt":"INVO Fertility, Inc.","displaySize":"","headline":null,"caption":"INVO Fertility, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/7597264acf7f316bc005ac3aa107b273"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bAHKwoixsVIBdBGpWthJUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7597264acf7f316bc005ac3aa107b273","width":300,"height":70}},"lazy":false},{"type":"text","content":"SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company’s proprietary INVOcell device. The new patent extends intellectual property protection on the Company’s INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to simplify use of the device.","length":525,"tagName":"p"},{"type":"text","content":"The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/949,960, titled "Intravaginal Culture Incubation Container and Method." The Notice of Allowance, dated June 17, 2025, indicates that the USPTO has completed its examination and found the claims patentable. Once the issue fee is paid, the patent will be granted and published, providing protection to the claimed invention for 20 years from the filing date.","length":488,"tagName":"p"},{"type":"text","content":"INVOcell is the world’s first FDA-cleared intravaginal culture (IVC) system, a patented medical device that enables fertilization and early embryo development to occur within a woman’s body, offering a more natural and intimate alternative to traditional in vitro fertilization (IVF). During the INVOcell procedure, eggs and sperm are placed in the thumb-sized device, which is then inserted into the vaginal cavity, typically, for a 5-day incubation period, utilizing the body’s natural environment as an incubator. After incubation, embryos are transferred to the uterus, with any remaining embryos available for freezing. This innovative approach delivers comparable pregnancy rates to IVF—as reflected in the Co...

More updates from Invo Fertility, Inc.

United States Patent and Trademark OfficeThe Companymedical devicefertility treatmentintellectual property protectionhealthcare companynotice of allowanceincubation periodINVO Fertilitynatural environment